# Standard Moderately Hypofractionated RT vs. Ultra-hypofractionated Focal Lesion Ablative Microboost in Prostate Cancer

> **NCT05705921** · NA · RECRUITING · sponsor: **The Netherlands Cancer Institute** · enrollment: 484 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **RADIATION:** Radiotherapy standard
- **RADIATION:** Radiotherapy Hypo-FLAME

## Key facts

- **NCT ID:** NCT05705921
- **Lead sponsor:** The Netherlands Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-26
- **Primary completion:** 2032-01-01
- **Final completion:** 2032-01-01
- **Target enrollment:** 484 (ESTIMATED)
- **Last updated:** 2026-01-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05705921

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05705921, "Standard Moderately Hypofractionated RT vs. Ultra-hypofractionated Focal Lesion Ablative Microboost in Prostate Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05705921. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*